Vital Therapies, Inc.
10
0
0
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
50.0%
5 terminated/withdrawn out of 10 trials
44.4%
-42.1% vs industry average
30%
3 trials in Phase 3/4
100%
4 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (10)
To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure
Role: lead
Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure
Role: lead
Safety and Efficacy of the ELAD System (ELAD) to Treat Acute Liver Failure (ALF)
Role: lead
Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD
Role: lead
Registry Protocol for Tracking Trial Subjects After VTI-206 Study Completion
Role: lead
Use of the ELAD® in Patients With Liver Failure to Provide Expanded Access With Cost Recovery
Role: lead
Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patients With Hepatic Insufficiency
Role: lead
Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis
Role: lead
Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure
Role: lead
Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)
Role: lead
All 10 trials loaded